Name: TRAJECTOME Research Group
Title of the Project: Temporal disease map based stratification of depression-related multimorbidities: towards quantitative investigations of patient trajectories and predictions of multi-target drug candidates
Acronym: TRAJECTOME
Project Coordinator:
Semmelweis University, Department of Pharmacodynamics
Dr. Gabriella Juhász PhD, associate professor
E-mail: juhasz.gabriella@semmelweis.hu
Tel: +36 1 459 1500
Project Partners:
- Abiomics Europe Ltd., Budapest, Hungary, Dr. Péter Antal
- The Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland, Dr. Mikko Kuokkanen
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) – Hospital Clinic de Barcelona, Barcelona, Spain, Dr. Josep Roca
- Department of Psychiatry, University Medicine Greifswald (UMG), Greifswald, Mecklenburg-West Pomerania, Germany, Dr. rer. med. Sandra Van der Auwera-Palitschka
Start Date of the Project: 1 May 2020
End date of the project: 30 April 2023
Call of the Project: ERA PerMed Joint Translational Call 2019, “Personalised Medicine: Multidisciplinary Research Towards Implementation” (No. ERAPERMED2019-108)
Additional information: https://erapermed.isciii.es/
Funded by: NKFIH (contract number: 2019-2.1.7-ERA-NET-2020-00005)
Project Budget for the consortium: EUR 1.115M
About the Research
Depression is a commonly occurring mental disorder that usually have a chronic recurrent course throughout the life causing extensive sufferings to the patients. Previous studies suggest that depressed patients are prone to develop several other disorders, so called multimorbidities, most likely due to common biological and environmental risk factors.
The aim of the TRAJECTOME project is to investigate how these multimorbidities emerge in time in order to identify disease trajectories.
These disease trajectories will help to distinguish depressed patients with similar multimorbidity profiles and identify which specific biological, socioeconomic and lifestyle factors contribute to the development of their symptoms. By understanding these processes, the TRAJECTOME project will enable improved disease prediction and prevention in depression and also provide new insight for drug discovery to promote personalized medicine in depression related multimorbidities.
Explanatory figure of the TRAJECTOME project
(EraPerMed Newsletter, January, 2020,https://erapermed.isciii.es/wp-content/uploads/2020/02/NEWSLETTER-3-final.pdf)